Lexeo Therapeutics, Inc. (LXEO) — 8-K Filings

8-K Filings (22)

• 8-K Filing — May 11, 2026
• 8-K Filing — Apr 30, 2026
• 8-K Filing — Mar 30, 2026
• Lexeo Therapeutics Files 8-K: Material Agreement, Financials — Oct 17, 2025 Risk: medium
  Lexeo Therapeutics, Inc. announced on October 16, 2025, the entry into a material definitive agreement. The company also reported on its results of operations a
• Lexeo Therapeutics Files 8-K — Oct 7, 2025 Risk: low
  Lexeo Therapeutics, Inc. filed an 8-K on October 7, 2025, reporting on various events. The filing includes information related to Regulation FD disclosures, oth
• Lexeo Therapeutics Files 8-K on Security Holder Vote — Jun 30, 2025 Risk: low
  Lexeo Therapeutics, Inc. filed an 8-K on June 30, 2025, reporting a submission of matters to a vote of security holders. The filing does not contain specific de
• Lexeo Therapeutics Files 8-K: Material Agreement & Equity Sales — May 27, 2025 Risk: medium
  Lexeo Therapeutics, Inc. announced on May 27, 2025, that it entered into a material definitive agreement. The company also disclosed unregistered sales of equit
• Lexeo Therapeutics Files 8-K — Apr 7, 2025 Risk: low
  Lexeo Therapeutics, Inc. filed an 8-K on April 7, 2025, reporting on other events and financial statements. The filing does not contain specific details about n
• Lexeo Therapeutics Files 8-K on Financials — Mar 24, 2025 Risk: low
  Lexeo Therapeutics, Inc. filed an 8-K on March 24, 2025, reporting on its results of operations and financial condition. The filing includes financial statement
• Lexeo Therapeutics Files 8-K — Jan 13, 2025 Risk: low
  Lexeo Therapeutics, Inc. filed an 8-K on January 13, 2025, reporting its status as a registrant. The filing confirms its common stock trades under the symbol LX
• Lexeo Therapeutics Files 8-K for Director/Officer Changes — Dec 19, 2024 Risk: low
  Lexeo Therapeutics, Inc. filed an 8-K on December 18, 2024, reporting changes related to its board of directors and officers, as well as compensatory arrangemen
• Lexeo Therapeutics Files 8-K — Nov 13, 2024 Risk: low
  Lexeo Therapeutics, Inc. filed an 8-K on November 13, 2024, reporting on results of operations, financial condition, and changes in directors and officers. The
• 8-K Filing — Oct 30, 2024
• Lexeo Therapeutics Files 8-K — Oct 9, 2024 Risk: low
  Lexeo Therapeutics, Inc. filed an 8-K on October 9, 2024, reporting other events and financial statements. The filing does not disclose specific new events or f
• Lexeo Therapeutics Files 8-K — Jul 15, 2024 Risk: low
  Lexeo Therapeutics, Inc. filed an 8-K on July 15, 2024, to report other events and financial statements. The filing does not contain specific details about the
• Lexeo Therapeutics Appoints New CMO, Director — Jul 8, 2024 Risk: medium
  Lexeo Therapeutics, Inc. announced on July 8, 2024, the appointment of Dr. Christopher Adams as Chief Medical Officer and the election of Ms. Sarah Kelly to its
• Lexeo Therapeutics Files 8-K on Shareholder Votes — Jun 28, 2024 Risk: low
  Lexeo Therapeutics, Inc. filed an 8-K on June 28, 2024, to report on matters submitted to a vote of its security holders. The filing indicates that the company
• Lexeo Therapeutics Files 8-K: Material Definitive Agreement — Apr 22, 2024 Risk: medium
  Lexeo Therapeutics, Inc. announced on April 22, 2024, that it entered into a Material Definitive Agreement. The filing also includes other events and financial
• Lexeo Therapeutics Appoints New Directors, Adjusts Executive Pay — Apr 22, 2024 Risk: medium
  Lexeo Therapeutics, Inc. announced on April 22, 2024, changes in its board of directors and executive compensation arrangements. Specifically, the company elect
• Lexeo Therapeutics Files 8-K — Apr 16, 2024 Risk: low
  Lexeo Therapeutics, Inc. filed an 8-K on April 16, 2024, reporting other events and financial statements. The company, incorporated in Delaware with its princip
• Lexeo Therapeutics Files 8-K: Agreements, Financials, Equity Sales — Mar 11, 2024 Risk: medium
  On March 11, 2024, Lexeo Therapeutics, Inc. filed an 8-K report detailing several key events. The company entered into a material definitive agreement, reported
• Lexeo Therapeutics Confirms 'Emerging Growth Company' Status — Feb 5, 2024
  Lexeo Therapeutics, Inc. filed an 8-K on February 5, 2024, primarily to disclose that it is an "emerging growth company." This designation, under the Securities

Popular Companies

AAPL · TSLA · MSFT · AMZN · GOOGL · META · NVDA · JPM · BRK-B · V · JNJ · UNH · XOM · WMT · MA · PG · HD · DIS · BAC · NFLX